Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Glomerular Filtration Rate/ drug effects"'
Autor:
Dapa-Ckd Trial Committees, David C. Wheeler, John J.V. McMurray, C. David Sjöström, Peter Rossing, Glenn M. Chertow, Niels Jongs, Anna Maria Langkilde, Hiddo J.L. Heerspink, Robert D. Toto, Ricardo Correa-Rotter, Investigators, Bergur V. Stefánsson, Tom Greene
Publikováno v:
Lancet Diabetes & Endocrinology, 9(11), 743-754. ELSEVIER SCIENCE INC
BACKGROUND: Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified analysis, we assessed the effect of dapagliflozin on the rate of change
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7777b1dcd5c00a7f5f10476884f5566f
https://doi.org/10.1016/s2213-8587(21)00242-4
https://doi.org/10.1016/s2213-8587(21)00242-4
Autor:
Jens Faber, Jesper Jensen, Mariam Elmegaard Malik, Christian Tuxen, Lars Thorbjørn Jensen, Lars Køber, Niels Eske Bruun, Morten Schou, Ida Gustafsson, Emil L. Fosbøl, Finn Gustafsson, Caroline Kistorp, Julie Lyng Forman, Massar Omar, Jacob E. Møller
Publikováno v:
Jensen, J, Omar, M, Kistorp, C, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Faber, J, Malik, M E, Fosbøl, E L, Bruun, N E, Forman, J L, Jensen, L T, Møller, J E & Schou, M 2021, ' Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal) : a prespecified substudy of a double-blind, randomised, placebo-controlled trial ', The Lancet Diabetes & Endocrinology, vol. 9, no. 2, pp. 106-116 . https://doi.org/10.1016/S2213-8587(20)30382-X
Jensen, J, Omar, M, Kistorp, C, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Faber, J, Malik, M E, Fosbøl, E L, Bruun, N E, Forman, J L, Jensen, L T, Møller, J E & Schou, M 2021, ' Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal) : a prespecified substudy of a double-blind, randomised, placebo-controlled trial ', The Lancet Diabetes and Endocrinology, vol. 9, no. 2, pp. 106-116 . https://doi.org/10.1016/S2213-8587(20)30382-X
Jensen, J, Omar, M, Kistorp, C, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Faber, J, Malik, M E, Fosbøl, E L, Bruun, N E, Forman, J L, Jensen, L T, Møller, J E & Schou, M 2021, ' Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal) : a prespecified substudy of a double-blind, randomised, placebo-controlled trial ', The Lancet Diabetes and Endocrinology, vol. 9, no. 2, pp. 106-116 . https://doi.org/10.1016/S2213-8587(20)30382-X
BACKGROUND: SGLT2 inhibitors are a promising treatment option in patients with heart failure and reduced ejection fraction. We aimed to investigate the effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c49fee5041679414e31800f12e9b4f4d
https://doi.org/10.1016/s2213-8587(20)30382-x
https://doi.org/10.1016/s2213-8587(20)30382-x
Autor:
Niels Jongs, Bergur V. Stefánsson, Ricardo Correa-Rotter, Robert D. Toto, John J.V. McMurray, Tom Greene, Dapa-Ckd Trial Committees, C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink, David C. Wheeler, Glenn M. Chertow, Investigators, Peter Rossing
Publikováno v:
Lancet Diabetes & Endocrinology, 9(11), 755-766. ELSEVIER SCIENCE INC
BACKGROUND: Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin significantly reduced albuminuria in patients with type 2 diabetes and norm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b89091bdd4249d265893bbdc171c8e7e
https://research.rug.nl/en/publications/c2af467f-022b-4ad1-a4f9-5caab2e93272
https://research.rug.nl/en/publications/c2af467f-022b-4ad1-a4f9-5caab2e93272
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Heerspink, Hiddo J.L., Stefánsson, Bergur V., Correa-Rotter, Ricardo, Chertow, Glenn M., Greene, Tom, Hou, Fan-Fan, Mann, Johannes F.E., McMurray, John J.V., Lindberg, Magnus, Rossing, Peter, Sjöström, C. David, Toto, Roberto D., Langkilde, Anna-Maria, Wheeler, David C., Cruzado, Josep Ma.
Publikováno v:
New England Journal of Medicine, 383(15), 1436-1446. MASSACHUSETTS MEDICAL SOC
Heerspink, H J L, Stefánsson, B V, Correa-Rotter, R, Chertow, G M, Greene, T, Hou, F-F, Mann, J F E, McMurray, J J V, Lindberg, M, Rossing, P, Sjöström, C D, Toto, R D, Langkilde, A-M, Wheeler, D C & DAPA-CKD Trial Committees and Investigators 2020, ' Dapagliflozin in Patients with Chronic Kidney Disease ', The New England Journal of Medicine, vol. 383, no. 15, pp. 1436-1446 . https://doi.org/10.1056/NEJMoa2024816
Dipòsit Digital de la UB
Universidad de Barcelona
Heerspink, H J L, Stefánsson, B V, Correa-Rotter, R, Chertow, G M, Greene, T, Hou, F-F, Mann, J F E, McMurray, J J V, Lindberg, M, Rossing, P, Sjöström, C D, Toto, R D, Langkilde, A-M, Wheeler, D C & DAPA-CKD Trial Committees and Investigators 2020, ' Dapagliflozin in Patients with Chronic Kidney Disease ', The New England Journal of Medicine, vol. 383, no. 15, pp. 1436-1446 . https://doi.org/10.1056/NEJMoa2024816
Dipòsit Digital de la UB
Universidad de Barcelona
Background: \ud Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.\ud Methods: \ud W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88a9f07a611f740aec4f679c65611f94
https://research.rug.nl/en/publications/1def9c25-613d-4882-b619-e4099c6307a2
https://research.rug.nl/en/publications/1def9c25-613d-4882-b619-e4099c6307a2
Autor:
David C. Wheeler, Qiang Li, Brendon L. Neuen, Dick de Zeeuw, David R. Matthews, Meg Jardine, Kenneth W. Mahaffey, Bruce Neal, Toshiaki Ohkuma, Vlado Perkovic, Jaime Blais, Greg Fulcher
Publikováno v:
American Journal of Kidney Diseases, 77(1), 23-34.e1. W B SAUNDERS CO-ELSEVIER INC
34.e1
34.e1
RATIONALE & OBJECTIVE: Canagliflozin reduces the risk for cardiovascular and kidney outcomes in type 2 diabetes. This study aimed to assess the relative and absolute effects of canagliflozin on clinical outcomes across different KDIGO (Kidney Disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7286628e3f2c922b7c17c1d7e3b8a4cf
https://pubmed.ncbi.nlm.nih.gov/33342463
https://pubmed.ncbi.nlm.nih.gov/33342463
Autor:
Julie Steen Pedersen, Flemming Bendtsen, Lise Lotte Gluud, Troels M. Busk, Nina Kimer, Aleksander Krag, Sören Möller, Lise Hobolth
Publikováno v:
Kimer, N, Pedersen, J S, Busk, T M, Gluud, L L, Hobolth, L, Krag, A, Møller, S, Bendtsen, F & Copenhagen Rifaximin (CoRif) Study Group 2017, ' Rifaximin has no effect on hemodynamics in decompensated cirrhosis : A randomized, double-blind, placebo-controlled trial ', Hepatology, vol. 65, no. 2, pp. 592–603 . https://doi.org/10.1002/hep.28898
Decompensated cirrhosis is characterized by disturbed systemic and splanchnic hemodynamics. Bacterial translocation from the gut is considered the key driver in this process. Intestinal decontamination with rifaximin may improve hemodynamics. This do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::234bc6d642d78ac0d4f5a6790d0a9014
https://doi.org/10.1002/hep.28898
https://doi.org/10.1002/hep.28898
Autor:
Frederik H. Verbrugge
Publikováno v:
European heart journal. Acute cardiovascular care. 7(4)
Diuretic resistance is a powerful predictor of adverse outcome in acute heart failure (AHF), irrespectively of underlying glomerular filtration rate. Metrics of diuretic efficacy such as natriuresis, urine output, weight loss, net fluid balance, or f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c38472a8e592f94b8fe9845e78964a86
https://pubmed.ncbi.nlm.nih.gov/29897275
https://pubmed.ncbi.nlm.nih.gov/29897275
Autor:
Helle C. Thiesson, Line Aas Mortensen, Claus Bistrup, Birgitte Tougaard, Anne Sophie Lind Fischer, Martin Egfjord
Publikováno v:
Mortensen, L A, Thiesson, H C, Tougaard, B, Egfjord, M, Fischer, A S L & Bistrup, C 2018, ' The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity : A multicenter randomized, double-blind, clinical trial (the SPIREN trial) ', BMC Nephrology, vol. 19, no. 1, 105 . https://doi.org/10.1186/s12882-018-0885-6
BMC Nephrology, Vol 19, Iss 1, Pp 1-7 (2018)
BMC Nephrology
Mortensen, L A, Thiesson, H C, Tougaard, B, Egfjord, M, Fischer, A S L & Bistrup, C 2018, ' The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity : a multicenter randomized, double-blind, clinical trial (the SPIREN trial) ', BMC Nephrology, vol. 19, no. 1, 105, pp. 1-7 . https://doi.org/10.1186/s12882-018-0885-6
BMC Nephrology, Vol 19, Iss 1, Pp 1-7 (2018)
BMC Nephrology
Mortensen, L A, Thiesson, H C, Tougaard, B, Egfjord, M, Fischer, A S L & Bistrup, C 2018, ' The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity : a multicenter randomized, double-blind, clinical trial (the SPIREN trial) ', BMC Nephrology, vol. 19, no. 1, 105, pp. 1-7 . https://doi.org/10.1186/s12882-018-0885-6
BACKGROUND: Calcineurin inhibitor induced nephrotoxicity contributes to late allograft failure in kidney transplant patients. Evidence points towards aldosterone to play a role in the development of fibrosis in multiple organs. Animal studies have in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68d2f716fbb9fb36d1fd10f08b4e0596
https://findresearcher.sdu.dk:8443/ws/files/141325192/The_effect_of_spironolactone_on_calcineurin_inhibitor_induced_nephrotoxicity.pdf
https://findresearcher.sdu.dk:8443/ws/files/141325192/The_effect_of_spironolactone_on_calcineurin_inhibitor_induced_nephrotoxicity.pdf
Autor:
Pernille Lund Hansen, Anne D Thuesen, Majken Cardel, Henrik J. Andersen, Anja Toft, Peter Bie, Boye L. Jensen, Niels Marcussen, Walter S
Publikováno v:
Thuesen, A D, Andersen, H, Cardel, M, Toft, A, Walter, S, Marcussen, N, Jensen, B L, Bie, P & Hansen, P B L 2014, ' Differential effect of T-type voltage-gated Ca 2+ channel disruption on renal plasma flow and glomerular filtration rate in vivo ', American Journal of Physiology: Renal Physiology, vol. 307, no. 4, pp. F445-F452 . https://doi.org/10.1152/ajprenal.00016.2014
Voltage-gated Ca2+ (Cav) channels play an essential role in the regulation of renal blood flow and glomerular filtration rate (GFR). Because T-type Cav channels are differentially expressed in pre- and postglomerular vessels, it was hypothesized that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaaad1afbc2d7caf5eab973374e0be56
https://doi.org/10.1152/ajprenal.00016.2014
https://doi.org/10.1152/ajprenal.00016.2014